The French National Agency for Medicines and Health Products gave Nanobiotix the green light to start a Phase I/II trial in two new cancer populations for its lead product, NBTXR3. This could lead to an increase in the commercial potential of this promising French Biotech.
Nanobiotix is a great French Biotech company, which you can discover better in our exclusive interview of its charismatic CEO Laurent Levy.
This new phase I/II study will evaluate the use of NBTXR3 in hepatocellular cancer and liver metastases. In the clinical trial, the candidate will be activated with high precision radiation therapy, delivered as high dose fractions, known as Stereotatic Body Radiation Therapy.
This type of therapy is the safest and most modern radiotherapy currently available for the treatment of malignant liver tumors, although it has been shown to be efficient only in specific subsets of the population with small tumors.
Liver cancers are challenging diseases to address. Most patients, either with hepatocellular cancer or liver metastases, cannot benefit from surgery and have few or no therapeutic options available to them. Radiation therapy has been shown to improve clinical outcomes, including survival with clinical trials showing a direct correlation between higher doses of radiation therapy and better outcomes. The purpose of this clinical investigation is to introduce the use of NBTXR3 with Stereotatic Body Radiation Therapy in patients with liver cancers, who need an alternative treatment.
Nanobiotix has a great product in its hands and these new indications could increase its commercial potential even more.